Multiple sclerosis: Daclizumab HYP shows superiority to IFN-β1a for reducing relapses in multiple sclerosis. Nat Rev Neurol. 2015 Nov; 11(11):612. Epub 2015 Oct 27. PMID: 26503934. Abstract CommentRecommendBookmarkWatch